Our partners

English

Setting up drug discovery partnerships aimed at delivering clinical candidates is core to Inventiva’s strategy. These can be based on our internal programs as well as on our partners’ proprietary targets.

Abbvie Collaboration

Abbvie

In 2012 we signed a multi-year drug discovery collaboration with Abbvie which was extended in 2017. Within this collaboration, Inventiva leverages its discovery expertise and technology platforms to:

  • Deliver an IND-ready drug development candidate on RORg, an exciting new target with relevance in autoimmune diseases
  • Validate and provide leads in a series of targets of interest to our partner

This collaboration entitles Inventiva to receive research fees, milestones and sales royalties

Press-release

Boehringer Ingelheim Collaboration

 

In 2016 we signed a multi-year drug discovery collaboration with Boehringer Ingelheim to jointly validate a new therapeutic concept for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. In 2017 Boehringer-Ingelheim exercised an option to jointly discover novel therapeutic molecules modulating this now validated new target.  

This collaboration entitles Inventiva to receive research fees, milestones and sales royalties

Press-realease

Institut Curie Collaboration

Institut Curie

In 2014, we teamed up with Institut Curie to launch the Epicure project, with the financial support of France’s national research agency, the ANR (Agence Nationale pour la Recherche). The Epicure project focuses on two novel epigenetic targets implicated in immunomodulation. Epicure aims to confirm their therapeutic potential for the treatment of cancers such as breast cancer, ovarian cancer and melanoma, as well as some respiratory diseases. It also aims to identify molecules that are capable of regulating the activity of the targets and are therefore likely to become active drugs for the treatment of these diseases. The funding provided by the ANR covers a period of four years. The commercial rights to products developed under this collaboration belong to Inventiva.

Press-release